Gene · 1787
Papers1,524
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 1,524
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics. | Cancer Metastasis Rev | 2023 | 37369946 | PubTator, text mining | PubMed |
| The Effect of Nanomaterials on DNA Methylation: A Review. | Nanomaterials (Basel) | 2023 | 37368308 | PubTator, text mining | PubMed |
| Gene Expression Profiles of Methyltransferases and Demethylases Associated with Metastasis, Tumor Invasion, CpG73 Methylation, and HPV Status in Head and Neck Squamous Cell Carcinoma. | Curr Issues Mol Biol | 2023 | 37367043 | PubTator, text mining | PubMed |
| Revealing the roles of TLR7, a nucleic acid sensor for COVID-19 in pan-cancer. | Biosaf Health | 2023 | 37362864 | PubTator, text mining | PubMed |
| Effect of Zebularine on Apoptotic Pathways in Hepatocellular Carcinoma Cell Lines. | Int J Prev Med | 2023 | 37351028 | PubTator, text mining | PubMed |
| Small RNA modifications: regulatory molecules and potential applications. | J Hematol Oncol | 2023 | 37349851 | PubTator, text mining | PubMed |
| The Epigenetic Reader Methyl-CpG-Binding Protein 2 (MeCP2) Is an Emerging Oncogene in Cancer Biology. | Cancers (Basel) | 2023 | 37345019 | PubTator, text mining | PubMed |
| Molecular features, biological behaviors and clinical implications of m5C RNA methylation modification regulators in gastrointestinal cancers. | Cancer Biol Ther | 2023 | 37332118 | PubTator, text mining | PubMed |
| Vital roles of m5C RNA modification in cancer and immune cell biology. | Front Immunol | 2023 | 37325635 | PubTator, text mining | PubMed |
| Epigenetics of the Pathogenesis and Complications of Type 2 Diabetes Mellitus. | touchREV Endocrinol | 2023 | 37313245 | PubTator, text mining | PubMed |
| Covalent S-Adenosylhomocysteine-Based DNA Methyltransferase 2 Inhibitors with a New Type of Aryl Warhead. | ACS Med Chem Lett | 2023 | 37312859 | PubTator, text mining | PubMed |
| A pan-cancer analysis of the oncogenic and immunological roles of apolipoprotein F (APOF) in human cancer. | Eur J Med Res | 2023 | 37312170 | PubTator, text mining | PubMed |
| 5-Methylcytosine-related lncRNAs: predicting prognosis and identifying hot and cold tumor subtypes in head and neck squamous cell carcinoma. | World J Surg Oncol | 2023 | 37312123 | PubTator, text mining | PubMed |
| Pan-cancer analysis of Homeobox B9 as a predictor for prognosis and immunotherapy in human tumors. | Aging (Albany NY) | 2023 | 37301547 | PubTator, text mining | PubMed |
| Mechanisms of and Potential Medications for Oxidative Stress in Ovarian Granulosa Cells: A Review. | Int J Mol Sci | 2023 | 37298157 | PubTator, text mining | PubMed |
Underexplored reciprocity between genome-wide methylation status and long non-coding RNA expression reflected in breast cancer research: potential impacts for the disease management in the framework of 3P medicine. | EPMA J | 2023 | 37275549 | PubTator, text mining | PubMed |
| A multi-omics analysis reveals CLSPN is associated with prognosis, immune microenvironment and drug resistance in cancers. | Biol Proced Online | 2023 | 37268895 | PubTator, text mining | PubMed |
| Natural Bioactive Products as Epigenetic Modulators for Treating Neurodegenerative Disorders. | Pharmaceuticals (Basel) | 2023 | 37259364 | PubTator, text mining | PubMed |
| Epigenetic Regulation of Macrophage Polarization in Cardiovascular Diseases. | Pharmaceuticals (Basel) | 2023 | 37259293 | PubTator, text mining | PubMed |
| Comprehensively prognostic and immunological analysis of snail family transcriptional repressor 2 in pan-cancer and identification in pancreatic carcinoma. | Front Immunol | 2023 | 37251370 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1787/papers?page=10